Overview

• The NHS is conducting trials of the Galleri and miONCO-Dx blood tests, which use AI to detect up to 12 cancers at early stages before symptoms appear.
• New research published in BMJ Open suggests annual screening could reduce late-stage cancer diagnoses by 49% and cut five-year mortality by 21%.
• Biennial screening is less effective than annual tests, with 39% fewer late-stage diagnoses and a 17% reduction in mortality over five years.
• The miONCO-Dx test analyzes microRNA in blood samples to identify cancer presence and location, offering a minimally invasive alternative to traditional screenings.
• Researchers emphasize the need for large-scale randomized trials to validate these findings, with potential national rollout projected within a decade.